02:43 , Jan 25, 2017 |  BC Week In Review  |  Clinical News

AIC499: Ph I started

AiCuris began a single-blind, placebo-controlled, Austrian Phase I trial to evaluate single and multiple ascending doses of IV AIC499 in 48 healthy volunteers. The trial is being supported by the COMBACTE-MAGNET project from Innovative Medicines...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Company News

AiCuris, Basilea, AstraZeneca, GlaxoSmithKline, Sanofi, Innovative Medicines Initiative infectious news

IMI announced the seven-year, EUR167 million ($189 million) COMBACTE-MAGNET project under the New Drugs 4 Bad Bugs program, which will partner 33 European academic sites and five companies to develop two new antibacterials to combat...